HydroVax-001 (West Nile)
HydroVax-001 experimental vaccine was discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University (OHSU) in Portland.
The scientists were funded with a $7.2 million grant awarded in 2009 from NIAID, part of the National Institutes of Health.
The OHSU research team, led by senior scientist Mark Slifka, Ph.D., created the investigational vaccine, HydroVax-001, with a novel, hydrogen peroxide-based process that renders the virus inactive while still maintaining key immune-system triggering surface structures.
Because the virus used to make the vaccine is inactivated, the experimental vaccine likely could be used in a diverse population, including immunologically vulnerable groups, such as the elderly, NIAID said.